Gm711 Activators
Serine/threonine kinase-like domain containing 1 activators encompass a variety of compounds that influence cellular signaling pathways, leading to the enhancement of Stkld1 activity. These activators work through different mechanisms, primarily involving alterations in the phosphorylation status of Stkld1 or the modulation of upstream kinase activities. For instance, compounds like forskolin and rolipram target the cAMP-dependent pathway, with forskolin directly stimulating adenylate cyclase and rolipram inhibiting PDE4. This results in elevated cAMP levels and subsequent activation of PKA, a kinase that phosphorylates a spectrum of proteins, including Stkld1. Similarly, the PTH (1-34) fragment acts on the PTH1R receptor to increase cAMP and PKA activity, which also leads to the phosphorylation and activation of Stkld1.
Further, the activation of JNK by anisomycin can phosphorylate serine/threonine kinases, enhancing Stkld1 activity. When inhibitors like SB 203580 and U0126 are used, they can redirect intracellular signaling by inhibiting competing MAPK pathways or MEK1/2, respectively, potentially upregulating Stkld1 activity due to the interconnected nature of signaling networks. Phosphatidylinositol 3-kinase (PI3K) activity is modulated by LY294002, altering the balance of kinase activity and potentially favoring Stkld1 activation. The use of phosphatase inhibitors such as okadaic acid andCalyculin A leads to an increase in the overall phosphorylation status of cellular proteins, including serine/threonine kinases, which may result in the enhancement of Stkld1 kinase activity due to reduced dephosphorylation rates.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, increasing cAMP levels which can enhance PKA activity. PKA phosphorylates a wide range of targets including serine/threonine kinase-like domain-containing 1 (Stkld1), leading to its activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which increases intracellular cAMP by preventing its breakdown. Elevated cAMP activates PKA, which in turn can phosphorylate and enhance Stkld1 activity. | ||||||
Parathyroid hormone fragment (1-34) | 52232-67-4 | sc-487943 | 100 µg | $185.00 | ||
Parathyroid hormone fragment activates the PTH1R receptor, leading to cAMP production and PKA activation. PKA phosphorylates various proteins including Stkld1, enhancing its kinase activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP levels and PKA activation. PKA can phosphorylate Stkld1, increasing its activity. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine binds to the beta-adrenergic receptors, stimulating adenylate cyclase to increase cAMP and activate PKA. PKA then phosphorylates Stkld1, enhancing its function. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a JNK activator, and JNK pathway activation can lead to the phosphorylation of various serine/threonine kinases including Stkld1, enhancing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, and by inhibiting competing MAPK pathways, it can shunt signaling towards other serine/threonine kinases such as Stkld1, indirectly enhancing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which can shift the balance of kinase activity within the cell, potentially enhancing the activity of alternative kinases like Stkld1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, leading to altered signaling dynamics within the MAPK pathway that can indirectly result in the enhancement of Stkld1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which can modify the activity of serine/threonine kinases related to JNK signaling, potentially enhancing Stkld1 activity as the signaling milieu is adjusted. | ||||||